Immune response against SARS-CoV-2 variants: the role of neutralization assays

Abstract Since the emergence of the novel coronavirus SARS-CoV-2 in late 2019, the COVID-19 pandemic has hindered social life and global economic activity. As of July 2021, SARS-CoV-2 has caused over four million deaths. The rapid spread and high mortality of the disease demanded the international s...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Alicja Maria Chmielewska, Anna Czarnota, Krystyna Bieńkowska-Szewczyk, Katarzyna Grzyb
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/774dca0f71354bdcbe9d1aea2f8b0c23
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:774dca0f71354bdcbe9d1aea2f8b0c23
record_format	dspace
spelling	oai:doaj.org-article:774dca0f71354bdcbe9d1aea2f8b0c232021-12-05T12:05:31ZImmune response against SARS-CoV-2 variants: the role of neutralization assays10.1038/s41541-021-00404-62059-0105https://doaj.org/article/774dca0f71354bdcbe9d1aea2f8b0c232021-11-01T00:00:00Zhttps://doi.org/10.1038/s41541-021-00404-6https://doaj.org/toc/2059-0105Abstract Since the emergence of the novel coronavirus SARS-CoV-2 in late 2019, the COVID-19 pandemic has hindered social life and global economic activity. As of July 2021, SARS-CoV-2 has caused over four million deaths. The rapid spread and high mortality of the disease demanded the international scientific community to develop effective vaccines in a matter of months. However, unease about vaccine efficacy has arisen with the spread of the SARS-CoV-2 variants of concern (VOCs). Time- and cost-efficient in vitro neutralization assays are widely used to measure neutralizing antibody responses against VOCs. However, the extent to which in vitro neutralization reflects protection from infection remains unclear. Here, we describe common neutralization assays based on infectious and pseudotyped viruses and evaluate their role in testing neutralizing responses against new SARS-CoV-2 variants. Additionally, we briefly review the recent findings on the immune response elicited by available vaccines against major SARS-CoV-2 variants, including Alpha, Beta, Gamma, and Delta.Alicja Maria ChmielewskaAnna CzarnotaKrystyna Bieńkowska-SzewczykKatarzyna GrzybNature PortfolioarticleImmunologic diseases. AllergyRC581-607Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Vaccines, Vol 6, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Alicja Maria Chmielewska Anna Czarnota Krystyna Bieńkowska-Szewczyk Katarzyna Grzyb Immune response against SARS-CoV-2 variants: the role of neutralization assays
description	Abstract Since the emergence of the novel coronavirus SARS-CoV-2 in late 2019, the COVID-19 pandemic has hindered social life and global economic activity. As of July 2021, SARS-CoV-2 has caused over four million deaths. The rapid spread and high mortality of the disease demanded the international scientific community to develop effective vaccines in a matter of months. However, unease about vaccine efficacy has arisen with the spread of the SARS-CoV-2 variants of concern (VOCs). Time- and cost-efficient in vitro neutralization assays are widely used to measure neutralizing antibody responses against VOCs. However, the extent to which in vitro neutralization reflects protection from infection remains unclear. Here, we describe common neutralization assays based on infectious and pseudotyped viruses and evaluate their role in testing neutralizing responses against new SARS-CoV-2 variants. Additionally, we briefly review the recent findings on the immune response elicited by available vaccines against major SARS-CoV-2 variants, including Alpha, Beta, Gamma, and Delta.
format	article
author	Alicja Maria Chmielewska Anna Czarnota Krystyna Bieńkowska-Szewczyk Katarzyna Grzyb
author_facet	Alicja Maria Chmielewska Anna Czarnota Krystyna Bieńkowska-Szewczyk Katarzyna Grzyb
author_sort	Alicja Maria Chmielewska
title	Immune response against SARS-CoV-2 variants: the role of neutralization assays
title_short	Immune response against SARS-CoV-2 variants: the role of neutralization assays
title_full	Immune response against SARS-CoV-2 variants: the role of neutralization assays
title_fullStr	Immune response against SARS-CoV-2 variants: the role of neutralization assays
title_full_unstemmed	Immune response against SARS-CoV-2 variants: the role of neutralization assays
title_sort	immune response against sars-cov-2 variants: the role of neutralization assays
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/774dca0f71354bdcbe9d1aea2f8b0c23
work_keys_str_mv	AT alicjamariachmielewska immuneresponseagainstsarscov2variantstheroleofneutralizationassays AT annaczarnota immuneresponseagainstsarscov2variantstheroleofneutralizationassays AT krystynabienkowskaszewczyk immuneresponseagainstsarscov2variantstheroleofneutralizationassays AT katarzynagrzyb immuneresponseagainstsarscov2variantstheroleofneutralizationassays
_version_	1718372262580584448

Immune response against SARS-CoV-2 variants: the role of neutralization assays

Ejemplares similares